DeGen Medical, Inc.
$324.9K 204 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Endogastric Solutions, Inc
Endogastric Solutions, Inc reported $325,378.25 across General Payments, Research, and Ownership to 933 physicians and teaching hospitals across 935 transactions.
- $325.4K Above-median payer
- All-tracks total
- 935 Above-median volume
- Transactions
- 933 Above-median reach
- Recipients
- −$115.5K
- General Payments vs PY2023
Endogastric Solutions, Inc reported $325,378.25 across all CMS Open Payments tracks (General + Research + Ownership) to 933 physicians and teaching hospitals in Program Year 2024 - ranking #876 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $196,737.93, averaging $348.74 per recipient.
How Endogastric Solutions, Inc's $325.4K all-tracks total breaks down
Endogastric Solutions, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
18/100
Total payments
F
13/100
Transaction volume
F
17/100
Physician reach
F
17/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer endogastric-solutions-inc Endogastric Solutions, Inc
$325.4K · #876/1,925 · 0.0% industry · PY2024
- TOT $325.4K
- RANK #876
- SHARE 0.0%
- TXN 935
- RCP 933
- CAT 2
- GEN $196.7K
- ΔGEN −$115.5K
- TOP1 45.0%
- PY 2024
Volume peers
Nearest volume peer: DeGen Medical, Inc. ($324.9K)
Endogastric Solutions, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Endogastric Solutions, Inc's CMS-reported General Payments decreased by $115.5K (−37.0%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ENDOGASTRIC SOLUTIONS, INCPY2023: ENDOGASTRIC SOLUTIONS, INCPY2024: Endogastric Solutions, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $312,215.71
- PY2024
- $196,737.93
What the Data Shows for Endogastric Solutions, Inc
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Endogastric Solutions, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 2-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $157.8K, accounting for 80.2% of this company's General Payments and 36 transactions.
General Payment Breakdown by Type
Across 2 types of general payments, Endogastric Solutions, Inc's largest category was "Consulting Fee" at $157.8K - 80.2% of General Payments.
How Endogastric Solutions, Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $157.8K | 36 | 80.2% |
| Food and Beverage | $38.9K | 897 | 19.8% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $130,878.82 (66.5%) of $196,737.93 in this company's General Payments records across 735 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Endogastric Solutions, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Kenneth J Chang
$88,497.90 across 10 reported transactions
- 2
Ahmed Saeed
$13,565.08 across 7 reported transactions
- 3
Mohsin Soliman
$12,273.28 across 9 reported transactions
- 4
Brett Parker
$9,640.61 across 6 reported transactions
- 5
Venkataraman Muthusamy
$6,901.95 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Endogastric Solutions, Inc's spend rank (#876 of 1,925, top 46% by spend) and concentration rank (#721 of 1,838, top 39% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Servier BioInnovation : $2.1K total payments, HHI 2211
- Endovascular Engineering Inc. : $44.3K total payments, HHI 2208
- Body Vision Medical Inc. : $17.5K total payments, HHI 2201
- Zevra Therapeutics Inc : $34.8K total payments, HHI 2200
- Prexion, Inc. : $31.5K total payments, HHI 2195
- HT Medical, LLC : $28.7K total payments, HHI 2191
- Endogastric Solutions, Inc (this company) : $196.7K total payments, HHI 2176
- FUKUDA DENSHI Co., Ltd. : $8.8K total payments, HHI 2176
- imvaria inc. : $1.4K total payments, HHI 2173
- Biedermann Motech, Inc. : $7.7K total payments, HHI 2168
- Embecta Corp. : $245.4K total payments, HHI 2146
- Allerderm Laboratories : $9.2K total payments, HHI 2140
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Endogastric Solutions, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Endogastric Solutions, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Endogastric Solutions, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
BioCryst Pharmaceuticals, Inc.
$326.1K 188 recipients
Compare payment profiles
Brainsway USA INC
$326.1K 242 recipients
Compare payment profiles
Life Spine, Inc.
$327.4K 429 recipients
Compare payment profiles
MedAlliance LLC
$323.3K 0 recipients
Compare payment profiles
Joint Jack Company LLC
$323.1K 0 recipients
Compare payment profiles
Put this to use
Endogastric Solutions, Inc ranks #876 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Endogastric Solutions, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.